(Q50852120)

English

Quantum dot-based in situ simultaneous molecular imaging and quantitative analysis of EGFR and collagen IV and identification of their prognostic value in triple-negative breast cancer.

scientific article published on 19 September 2015

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/26385773

Quantum dot-based in situ simultaneous molecular imaging and quantitative analysis of EGFR and collagen IV and identification of their prognostic value in triple-negative breast cancer. (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/26385773

0 references

author name string

Hong-Mei Zheng

1

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/26385773

Chuang Chen

2

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/26385773

Xin-Hong Wu

3

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/26385773

Jian Chen

4

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/26385773

Si Sun

5

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/26385773

Jin-Zhong Sun

6

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/26385773

Ming-Wei Wang

7

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/26385773

Sheng-Rong Sun

8

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/26385773

publication date

19 September 2015

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/26385773

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/26385773

37

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/26385773

2

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/26385773

2509-2518

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/26385773

Global cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4079-6

21 January 2018

Treatment of triple negative breast cancer (TNBC): current options and future perspectives

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4079-6

21 January 2018

Molecular stratification of triple-negative breast cancers.

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4079-6

21 January 2018

Subtyping of triple-negative breast cancer: implications for therapy

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4079-6

21 January 2018

Heterogeneity of triple-negative breast cancer: histologic subtyping to inform the outcome.

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4079-6

21 January 2018

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4079-6

21 January 2018

Tapping the potential of quantum dots for personalized oncology: current status and future perspectives

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4079-6

21 January 2018

Quantum dots-based tissue and in vivo imaging in breast cancer researches: current status and future perspectives

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4079-6

21 January 2018

Quantum dot-based immunofluorescent imaging of Ki67 and identification of prognostic value in HER2-positive (non-luminal) breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4079-6

21 January 2018

Quantum dots-based molecular classification of breast cancer by quantitative spectroanalysis of hormone receptors and HER2.

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4079-6

21 January 2018

The quantitative detection of total HER2 load by quantum dots and the identification of a new subtype of breast cancer with different 5-year prognosis.

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4079-6

21 January 2018

Quantum-dots based simultaneous detection of multiple biomarkers of tumor stromal features to predict clinical outcomes in gastric cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4079-6

21 January 2018

Quantum dots-based in situ molecular imaging of dynamic changes of collagen IV during cancer invasion

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4079-6

21 January 2018

Quantum dots-based double-color imaging of HER2 positive breast cancer invasion.

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4079-6

21 January 2018

Tumor invasion unit in gastric cancer revealed by QDs-based in situ molecular imaging and multispectral analysis.

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4079-6

21 January 2018

Protease-dependent versus -independent cancer cell invasion programs: three-dimensional amoeboid movement revisited

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4079-6

21 January 2018

Basement membranes: structure, assembly and role in tumour angiogenesis

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4079-6

21 January 2018

Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4079-6

21 January 2018

TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4079-6

21 January 2018

Breaching the basement membrane: who, when and how?

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4079-6

21 January 2018

Novel prognostic markers for patients with triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4079-6

21 January 2018

Microenvironmental regulation of metastasis

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4079-6

21 January 2018

The prognostic value of tumour-stroma ratio in triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4079-6

21 January 2018

Microenvironmental regulation of tumor progression and metastasis

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4079-6

21 January 2018

Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients.

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4079-6

21 January 2018

Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks.

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4079-6

21 January 2018

P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4079-6

21 January 2018

Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4079-6

21 January 2018

Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4079-6

21 January 2018

Androgen receptor in triple negative breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4079-6

21 January 2018

Prognostic value of Ki-67 proliferating index in triple negative breast carcinomas

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4079-6

21 January 2018

Co-expression of cancer testis antigens and topoisomerase 2-alpha in triple negative breast carcinomas.

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4079-6

21 January 2018

New treatment strategies for patients with triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4079-6

21 January 2018

Biological subtypes of triple-negative breast cancer are associated with distinct morphological changes and clinical behaviour

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4079-6

21 January 2018

Patterns of cancer invasion revealed by QDs-based quantitative multiplexed imaging of tumor microenvironment

1 reference

https://pubmed.ncbi.nlm.nih.gov/26385773

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quantum dot-based multiplexed imaging in malignant ascites: a new model for malignant ascites classification

1 reference

https://pubmed.ncbi.nlm.nih.gov/26385773

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The clonal and mutational evolution spectrum of primary triple-negative breast cancers

1 reference

https://pubmed.ncbi.nlm.nih.gov/26385773

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quantum dots-based immunofluorescence technology for the quantitative determination of HER2 expression in breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/26385773

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumor microenvironment of metastasis and risk of distant metastasis of breast cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26385773

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quantum-dot-based immunofluorescent imaging of HER2 and ER provides new insights into breast cancer heterogeneity

1 reference

https://pubmed.ncbi.nlm.nih.gov/26385773

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quantum dots-based quantitative and in situ multiple imaging on ki67 and cytokeratin to improve ki67 assessment in breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/26385773

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quantum dot-based quantitative immunofluorescence detection and spectrum analysis of epidermal growth factor receptor in breast cancer tissue arrays

1 reference

https://pubmed.ncbi.nlm.nih.gov/26385773

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S13277-015-4079-6

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/26385773

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 March 2018

http://europepmc.org/abstract/MED/26385773

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50852120&oldid=2210527379"